Medwell Capital
Medwell Capital Corp. (formerly BioMS Medical Corp) (TSX-V: WMC) is a Canadian biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of Multiple Sclerosis. On July 27, 2009 the company announced that its drug, dirucotide, failed to meet its primary endpoint in the Phase III MAESTRO-01 Trial. It will discontinue testing of the drug and the future of the company is unclear.
Read more about Medwell Capital: Development, Partnership, Clinical Trials, See Also
Famous quotes containing the word capital:
“It is a capital blunder; as you discover, when another man recites his charities.”
—Ralph Waldo Emerson (1803–1882)